Arbutus to Report First Quarter 2021 Financial Results and Provide Corporate Update
Arbutus Biopharma Corporation (Nasdaq: ABUS) has announced its first quarter 2021 financial results and corporate update scheduled for May 5, 2021. Key details include the release of the financial results at 7:30 a.m. ET followed by a conference call/webcast at 8:45 a.m. ET. The domestic dial-in number for the call is (866) 393-1607, and international callers can reach (914) 495-8556 with conference ID 4445858. Arbutus focuses on developing treatments for chronic hepatitis B and coronaviruses.
- None.
- None.
WARMINSTER, Pa., April 28, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (including COVID-19), today announced that it has scheduled its first quarter 2021 financial results and corporate update for Wednesday, May 5, 2021. The schedule for the press release and conference call/webcast are as follows:
| • | 1Q/2021 Press Release: | Wednesday, May 5, 2021 at 7:30 a.m. ET |
| • | 1Q/2021 Conference Call/Webcast: | Wednesday, May 5, 2021 at 8:45 a.m. ET |
| • | Domestic Dial-In Number: | (866) 393-1607 |
| • | International Dial-In Number: | (914) 495-8556 |
| • | Conference ID Number: | 4445858 |
A live webcast of the conference call can be accessed through the Investors section of Arbutus' website at www.arbutusbio.com or directly at Live Webcast.
An archived webcast will be available on the Arbutus website after the event. Alternatively, you may access a replay of the conference call by calling (855) 859-2056 or (404) 537-3406, and reference conference ID: 4445858.
About Arbutus
Arbutus Biopharma Corporation is a publicly traded (Nasdaq: ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection. The Company is advancing multiple drug product candidates that may be combined into a potentially curative regimen for chronic HBV infection. Arbutus has also initiated a drug discovery and development effort for treating coronaviruses (including COVID-19). For more information, visit www.arbutusbio.com.
Contact Information
Investors and Media
William H. Collier
President and CEO
Phone: 267-469-0914
Email: ir@arbutusbio.com
Pam Murphy
Investor Relations Consultant
Phone: 267-469-0914
Email: ir@arbutusbio.com
FAQ
When will Arbutus Biopharma announce its first quarter 2021 financial results?
What time is the conference call for Arbutus Biopharma's Q1 2021 results?
What is the dial-in number for the Arbutus Biopharma conference call?
What is the conference ID for Arbutus Biopharma's Q1 2021 call?
